Table 5.
Summary of degrader drugs under clinical evaluation in other disease entities. Red: active, not recruiting; yellow: recruiting; blue: completed; violet: not yet recruiting. AD: atopic dermatitis; AGA: androgenetic alopecia; AR: androgen receptor; HS: hidradenitis suppurativa; IKZF: IKAROS zinc-finger; IRAK4: interleukin-1 receptor-associated kinase 4; SLE: systemic lupus erythematosus.
| Time | Degrader | Target | Indication | NCT Number | Phase |
|---|---|---|---|---|---|
| 2017 2021 |
Avadomide | IKZF1/3 | Renal insufficiency Critical illness and sepsis |
NCT03097016
NCT05083520 |
Phase I |
| 2022 | GT20029 | AR | Acne vulgaris and AGA | NCT05428449 | Phase I |
| 2014 2017 2019 2021 2021 |
Iberdomide | IKZF1/3 | SLE SLE Hepatic impairment Renal insufficiency Critical illness and sepsis |
NCT02185040
NCT03161483 NCT03824678 NCT04933747 NCT05083520 |
Phase II Phase II Phase I Phase I |
| 2021 | KT-474 | IRAK4 | AD and HS | NCT04772885 | Phase I |